DigestRedComo funciona
Red
/
Empresas
Ur
No verificado

UroGen Pharma Ltd.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

42 Comunicados de prensa

Ver todos los comunicados de prensa
12/06/2025
Multimedia
Higiene alimentaria
Salud
Farmacéutica
Oncología
Industria
U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
06/06/2025
Mercado de valores
Finanzas
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
02/06/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
02/06/2025
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
27/05/2025
Biotecnología
Farmacéutica
Salud
Oncología
Web y redes sociales
Telefonía
Ferias y Congresos
Eventos
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
21/05/2025
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
12/05/2025
Web y redes sociales
Telefonía
Mercado de valores
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
01/05/2025
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
27/04/2025
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0
27/04/2025
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Fuente
UroGen Pharma Ltd.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0